Physician profile
Sony P John
NPI 1316109119
$3,203.77
in general payments reported to CMS, 2019-2025
39 companies · $640 in 2025
The $640 reported for 2025 was more than what 78% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $182 · 2021: $67.74 · 2022: $599 · 2023: $847 · 2024: $869 · 2025: $640.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,356.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,355.59 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $485.88 | 2021-2025 | |
| Novo Nordisk INC | $366.10 | 2021-2024 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $243.45 | 2019-2025 | Fasenra, Farxiga, Breztri |
| Lilly USA, LLC | $219.74 | 2022-2025 | Mounjaro, Zepbound, Trulicity |
| Astellas Pharma US INC | $212.54 | 2022-2025 | Veozah, Myrbetriq |
| Boehringer Ingelheim Pharmaceuticals, INC. | $157.40 | 2022-2025 | Jardiance, Ofev |
| Merck Sharp & Dohme LLC | $117.13 | 2019-2025 | Lagevrio, Gardasil 9, Capvaxive |
| Abbott Laboratories | $111.59 | 2023-2025 | Octrode, Freestyle Libre 3, Freestyle Libre 2 |
| Pfizer INC. | $107.06 | 2022-2024 | |
| Glaxosmithkline, LLC. | $106.43 | 2019-2025 | Trelegy Ellipta, Arexvy |
| Ironshore Pharmaceuticals INC. | $100.07 | 2021-2024 | |
| Dexcom, INC. | $92.39 | 2024-2025 | Dexcom G6 Transmitter |
| Teva Pharmaceuticals USA, INC. | $74.62 | 2022-2025 | Austedo Xr, Austedo Xr |
| Exact Sciences Corporation | $62.05 | 2023-2024 | Cologuard Collection Kit |
| Axsome Therapeutics, INC. | $60.49 | 2024-2025 | Auvelity, Symbravo |
Show all 39 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $56.06 | 2022-2025 | |
| Shield Therapeutics INC | $55.46 | 2025 | |
| Stryker Corporation | $44.72 | 2024 | Mild Device Kit |
| Neurocrine Biosciences, INC. | $44.54 | 2024 | Ingrezza |
| Inspire Medical Systems, INC. | $42.20 | 2025 | Inspire |
| Csl Behring | $39.17 | 2025 | Andembry |
| Otsuka America Pharmaceutical, INC. | $38.47 | 2023-2024 | Rexulti |
| Sanofi-Aventis U.S. LLC | $37.18 | 2023-2024 | |
| Amgen INC. | $36.69 | 2019 | |
| Tris Pharma INC | $33.18 | 2023-2024 | Dyanavel Xr |
| Almatica Pharma LLC | $25.36 | 2024 | Loreev Xr |
| Alexion Pharmaceuticals, INC. | $24.84 | 2022 | |
| Ibsa Pharma INC. | $24.46 | 2022 | |
| Phathom Pharmaceuticals, INC. | $23.30 | 2024 | Voquezna |
| Alkermes, INC. | $23.06 | 2022 | |
| Corium, LLC | $20.97 | 2022 | |
| Medtronic, INC. | $17.58 | 2023 | Inpen Smart Insulin Delivery System |
| Mirum Pharmaceuticals, INC. | $17.55 | 2023 | |
| Lundbeck LLC | $16.99 | 2023 | Rexulti |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $16.76 | 2025 | Caplyta |
| Bausch Health US, LLC | $14.60 | 2022 | |
| Sanofi Pasteur INC. | $12.54 | 2019 | |
| Allergan, INC. | $11.47 | 2019 | |
| Acarix USA INC. | $9.68 | 2023 | Cadscor System |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sony John listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.